Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer.

Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J, Irei I, Masuda T, Fukuda M, Kinoshita A, Matsushita H, Shimizu K, Nakata M, Hattori N, Yamaguchi H, Fukuda M, Nozawa R, Kakimi K, Oka M.

J Thorac Oncol. 2019 Aug 23. pii: S1556-0864(19)30691-4. doi: 10.1016/j.jtho.2019.08.008. [Epub ahead of print]

2.

Irreversible Electroporation versus Radiofrequency Ablation: Comparison of Systemic Immune Responses in Patients with Hepatocellular Carcinoma.

Sugimoto K, Kakimi K, Takeuchi H, Fujieda N, Saito K, Sato E, Sakamaki K, Moriyasu F, Itoi T.

J Vasc Interv Radiol. 2019 Jun;30(6):845-853.e6. doi: 10.1016/j.jvir.2019.03.002.

PMID:
31126596
3.

Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.

Nejo T, Matsushita H, Karasaki T, Nomura M, Saito K, Tanaka S, Takayanagi S, Hana T, Takahashi S, Kitagawa Y, Koike T, Kobayashi Y, Nagae G, Yamamoto S, Ueda H, Tatsuno K, Narita Y, Nagane M, Ueki K, Nishikawa R, Aburatani H, Mukasa A, Saito N, Kakimi K.

Cancer Immunol Res. 2019 Jul;7(7):1148-1161. doi: 10.1158/2326-6066.CIR-18-0599. Epub 2019 May 14.

PMID:
31088845
4.

In Vitro Assessment of Supersaturation/Precipitation and Biological Membrane Permeation of Poorly Water-Soluble Drugs: A Case Study With Albendazole and Ketoconazole.

Kataoka M, Takeyama S, Minami K, Higashino H, Kakimi K, Fujii Y, Takahashi M, Yamashita S.

J Pharm Sci. 2019 Aug;108(8):2580-2587. doi: 10.1016/j.xphs.2019.03.007. Epub 2019 Mar 15.

PMID:
30885658
5.

TCR Repertoire Analysis Reveals Mobilization of Novel CD8+ T Cell Clones Into the Cancer-Immunity Cycle Following Anti-CD4 Antibody Administration.

Aoki H, Ueha S, Shichino S, Ogiwara H, Hashimoto SI, Kakimi K, Ito S, Matsushima K.

Front Immunol. 2019 Jan 24;9:3185. doi: 10.3389/fimmu.2018.03185. eCollection 2018.

6.

Role of Toll-like Receptor 4 Expressed by Fibroblasts in Allograft Fibrosis in Mouse Orthotopic Tracheal Transplantation.

Kawashima M, Sato M, Murakawa T, Anraku M, Konoeda C, Hosoi A, Kakimi K, Nakajima J.

Transplant Proc. 2018 Dec;50(10):3863-3872. doi: 10.1016/j.transproceed.2018.06.023. Epub 2018 Jun 26.

PMID:
30577279
7.

[Re-Analysis of Cancer Vaccine Patients with Immune-Related Clinical Response Criteria(irRC)].

Nishida K, Saito T, Urakawa S, Mori M, Kakimi K, Doki Y, Wada H.

Gan To Kagaku Ryoho. 2018 Oct;45(10):1466-1468. Japanese.

PMID:
30382047
8.

High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma.

Karasaki T, Qiang G, Anraku M, Sun Y, Shinozaki-Ushiku A, Sato E, Kashiwabara K, Nagayama K, Nitadori JI, Sato M, Murakawa T, Kakimi K, Fukayama M, Nakajima J.

J Thorac Dis. 2018 Aug;10(8):4741-4750. doi: 10.21037/jtd.2018.07.45.

9.

Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.

Imai Y, Hasegawa K, Matsushita H, Fujieda N, Sato S, Miyagi E, Kakimi K, Fujiwara K.

Oncol Lett. 2018 May;15(5):6457-6468. doi: 10.3892/ol.2018.8101. Epub 2018 Feb 21.

10.

Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth.

Yamamoto M, Nomura S, Hosoi A, Nagaoka K, Iino T, Yasuda T, Saito T, Matsushita H, Uchida E, Seto Y, Goldenring JR, Kakimi K, Tatematsu M, Tsukamoto T.

Cancer Sci. 2018 May;109(5):1480-1492. doi: 10.1111/cas.13569. Epub 2018 Apr 15.

11.

Dendritic cell vaccine induces antigen-specific CD8+ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade.

Nagaoka K, Hosoi A, Iino T, Morishita Y, Matsushita H, Kakimi K.

Oncoimmunology. 2017 Nov 20;7(3):e1395124. doi: 10.1080/2162402X.2017.1395124. eCollection 2018.

12.

Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.

Hosoi A, Takeda K, Nagaoka K, Iino T, Matsushita H, Ueha S, Aoki S, Matsushima K, Kubo M, Morikawa T, Kitaura K, Suzuki R, Kakimi K.

Sci Rep. 2018 Jan 18;8(1):1058. doi: 10.1038/s41598-018-19548-y.

13.

NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer.

Hoshikawa M, Aoki T, Matsushita H, Karasaki T, Hosoi A, Odaira K, Fujieda N, Kobayashi Y, Kambara K, Ohara O, Arita J, Hasegawa K, Kakimi K, Kokudo N.

Biochem Biophys Res Commun. 2018 Jan 8;495(2):2058-2065. doi: 10.1016/j.bbrc.2017.12.083. Epub 2017 Dec 15.

PMID:
29253566
14.

The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.

Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K.

Oncoimmunology. 2017 Jun 16;6(8):e1338996. doi: 10.1080/2162402X.2017.1338996. eCollection 2017.

15.

Correction: CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated Exhaustion.

Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV.

PLoS Pathog. 2017 May 31;13(5):e1006416. doi: 10.1371/journal.ppat.1006416. eCollection 2017 May.

16.

Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation.

Ando K, Fujita H, Hosoi A, Ma L, Wakatsuki M, Seino KI, Kakimi K, Imai T, Shimokawa T, Nakano T.

J Radiat Res. 2017 Jul 1;58(4):446-455. doi: 10.1093/jrr/rrx005.

17.

Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer.

Aoki T, Matsushita H, Hoshikawa M, Hasegawa K, Kokudo N, Kakimi K.

Cytotherapy. 2017 Apr;19(4):473-485. doi: 10.1016/j.jcyt.2017.01.002. Epub 2017 Feb 7.

PMID:
28188072
18.

γδ T cell-based cancer immunotherapy.

Matsushita H, Kakimi K.

Nihon Rinsho. 2017 Feb;75(2):301-305. Japanese.

PMID:
30562868
19.

An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.

Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, Takazawa M, Ohara O, Kakimi K, Nakajima J.

J Thorac Oncol. 2017 May;12(5):791-803. doi: 10.1016/j.jtho.2017.01.005. Epub 2017 Jan 11.

20.

Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.

Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Takazawa M, Ohara O, Nakajima J, Kakimi K.

Cancer Sci. 2017 Feb;108(2):170-177. doi: 10.1111/cas.13131. Epub 2017 Feb 9.

21.

Correction: CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated Exhaustion.

Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV.

PLoS Pathog. 2016 Dec 7;12(12):e1006086. doi: 10.1371/journal.ppat.1006086. eCollection 2016 Dec.

22.

CD27(-)CD45(+) γδ T cells can be divided into two populations, CD27(-)CD45(int) and CD27(-)CD45(hi) with little proliferation potential.

Odaira K, Kimura SN, Fujieda N, Kobayashi Y, Kambara K, Takahashi T, Izumi T, Matsushita H, Kakimi K.

Biochem Biophys Res Commun. 2016 Sep 23;478(3):1298-303. doi: 10.1016/j.bbrc.2016.08.115. Epub 2016 Aug 21.

PMID:
27553282
23.

[Neoantigens and Whole-Exome Sequencing].

Karasaki T, Nakajima J, Kakimi K.

Gan To Kagaku Ryoho. 2016 Jul;43(7):791-7. Review. Japanese.

PMID:
27431622
24.

Advances in personalized cancer immunotherapy.

Kakimi K, Karasaki T, Matsushita H, Sugie T.

Breast Cancer. 2017 Jan;24(1):16-24. doi: 10.1007/s12282-016-0688-1. Epub 2016 Mar 21. Review.

PMID:
27000871
25.

MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma.

Makise N, Morikawa T, Nakagawa T, Ichimura T, Kawai T, Matsushita H, Kakimi K, Kume H, Homma Y, Fukayama M.

Hum Pathol. 2016 Apr;50:62-9. doi: 10.1016/j.humpath.2015.11.007. Epub 2015 Nov 28.

PMID:
26997439
26.

Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.

Matsushita H, Sato Y, Karasaki T, Nakagawa T, Kume H, Ogawa S, Homma Y, Kakimi K.

Cancer Immunol Res. 2016 May;4(5):463-71. doi: 10.1158/2326-6066.CIR-15-0225. Epub 2016 Mar 15.

27.

Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.

Karasaki T, Nagayama K, Kawashima M, Hiyama N, Murayama T, Kuwano H, Nitadori J, Anraku M, Sato M, Miyai M, Hosoi A, Matsushita H, Kikugawa S, Matoba R, Ohara O, Kakimi K, Nakajima J.

J Thorac Oncol. 2016 Mar;11(3):324-33. doi: 10.1016/j.jtho.2015.11.006. Epub 2015 Dec 29.

28.

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.

Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E.

Clin Cancer Res. 2015 Oct 1;21(19):4327-36. doi: 10.1158/1078-0432.CCR-15-0357.

29.
30.

Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically S-Cationized Full-Length and Water-Soluble Denatured Proteins.

Futami J, Nonomura H, Kido M, Niidoi N, Fujieda N, Hosoi A, Fujita K, Mandai K, Atago Y, Kinoshita R, Honjo T, Matsushita H, Uenaka A, Nakayama E, Kakimi K.

Bioconjug Chem. 2015 Oct 21;26(10):2076-84. doi: 10.1021/acs.bioconjchem.5b00328. Epub 2015 Sep 22.

PMID:
26355635
31.

Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.

Miyai M, Eikawa S, Hosoi A, Iino T, Matsushita H, Isobe M, Uenaka A, Udono H, Nakajima J, Nakayama E, Kakimi K.

PLoS One. 2015 Aug 20;10(8):e0136086. doi: 10.1371/journal.pone.0136086. eCollection 2015.

32.

Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma.

Sato Y, Shimizu K, Shinga J, Hidaka M, Kawano F, Kakimi K, Yamasaki S, Asakura M, Fujii SI.

Oncoimmunology. 2015 Jan 22;4(3):e995541. eCollection 2015 Mar.

33.

CTLs regulate tumor growth via cytostatic effects rather than cytotoxicity: a few T cells can influence the growth of many times more tumor cells.

Kakimi K, Matsushita H, Hosoi A, Miyai M, Ohara O.

Oncoimmunology. 2014 Dec 3;4(3):e970464. eCollection 2015 Mar.

34.

γδ T cell therapy for the treatment of non-small cell lung cancer.

Kakimi K, Matsushita H, Murakawa T, Nakajima J.

Transl Lung Cancer Res. 2014 Feb;3(1):23-33. doi: 10.3978/j.issn.2218-6751.2013.11.01. Review.

35.

Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.

Ueha S, Yokochi S, Ishiwata Y, Ogiwara H, Chand K, Nakajima T, Hachiga K, Shichino S, Terashima Y, Toda E, Shand FH, Kakimi K, Ito S, Matsushima K.

Cancer Immunol Res. 2015 Jun;3(6):631-40. doi: 10.1158/2326-6066.CIR-14-0190. Epub 2015 Feb 20.

36.

A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma.

Matsushita H, Enomoto Y, Kume H, Nakagawa T, Fukuhara H, Suzuki M, Fujimura T, Homma Y, Kakimi K.

J Immunother Cancer. 2014 Aug 19;2:30. doi: 10.1186/s40425-014-0030-4. eCollection 2014.

37.

Denatured mammalian protein mixtures exhibit unusually high solubility in nucleic acid-free pure water.

Futami J, Fujiyama H, Kinoshita R, Nonomura H, Honjo T, Tada H, Matsushita H, Abe Y, Kakimi K.

PLoS One. 2014 Nov 18;9(11):e113295. doi: 10.1371/journal.pone.0113295. eCollection 2014.

38.

Antitumor immunity by magnetic nanoparticle-mediated hyperthermia.

Kobayashi T, Kakimi K, Nakayama E, Jimbow K.

Nanomedicine (Lond). 2014 Aug;9(11):1715-26. doi: 10.2217/nnm.14.106. Review.

PMID:
25321171
39.

Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy.

Yamada D, Matsushita H, Azuma T, Nakagawa T, Nagata M, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Homma Y, Kakimi K.

Mol Clin Oncol. 2014 Nov;2(6):1023-1027. Epub 2014 Jul 29.

40.

Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest.

Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, Maekawa R, Matsushima K, Ohara O, Kakimi K.

Cancer Immunol Res. 2015 Jan;3(1):26-36. doi: 10.1158/2326-6066.CIR-14-0098. Epub 2014 Aug 15.

41.

High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy.

Kawai T, Enomoto Y, Morikawa T, Matsushita H, Kume H, Fukayama M, Yamaguchi H, Kakimi K, Homma Y.

Mol Clin Oncol. 2014 Jan;2(1):38-42. Epub 2013 Oct 18.

42.

Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.

Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, Kakimi K.

Cancer Med. 2014 Apr;3(2):362-75. doi: 10.1002/cam4.196. Epub 2014 Feb 7.

43.

Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.

Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E.

J Immunother. 2014 Feb-Mar;37(2):84-92. doi: 10.1097/CJI.0000000000000017.

PMID:
24509171
44.

Prognostic significance of CD204-positive macrophages in upper urinary tract cancer.

Ichimura T, Morikawa T, Kawai T, Nakagawa T, Matsushita H, Kakimi K, Kume H, Ishikawa S, Homma Y, Fukayama M.

Ann Surg Oncol. 2014 Jun;21(6):2105-12. doi: 10.1245/s10434-014-3503-2. Epub 2014 Feb 4.

PMID:
24492923
45.

Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.

Mizote Y, Uenaka A, Isobe M, Wada H, Kakimi K, Saika T, Kita S, Koide Y, Oka M, Nakayama E.

Vaccine. 2014 Feb 12;32(8):957-64. doi: 10.1016/j.vaccine.2013.12.042. Epub 2014 Jan 5.

PMID:
24397899
46.

Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.

Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, Kakimi K.

Int J Cancer. 2014 Apr 15;134(8):1810-22. doi: 10.1002/ijc.28506. Epub 2013 Oct 21.

47.

CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion.

Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV.

PLoS Pathog. 2013;9(7):e1003490. doi: 10.1371/journal.ppat.1003490. Epub 2013 Jul 11. Erratum in: PLoS Pathog. 2016 Dec 7;12 (12 ):e1006086. PLoS Pathog. 2017 May 31;13(5):e1006416.

48.

Epithelial to mesenchymal transition in murine tracheal allotransplantation: an immunohistochemical observation.

Konoeda C, Koinuma D, Morishita Y, Sano A, Nagayama K, Motomura N, Kakimi K, Miyazono K, Nakajima J, Nicolls MR, Murakawa T.

Transplant Proc. 2013 Jun;45(5):1797-801. doi: 10.1016/j.transproceed.2012.11.024.

49.

Tumor growth suppression by gadolinium-neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent.

Dewi N, Yanagie H, Zhu H, Demachi K, Shinohara A, Yokoyama K, Sekino M, Sakurai Y, Morishita Y, Iyomoto N, Nagasaki T, Horiguchi Y, Nagasaki Y, Nakajima J, Ono M, Kakimi K, Takahashi H.

Biomed Pharmacother. 2013 Jul;67(6):451-7. doi: 10.1016/j.biopha.2012.11.010. Epub 2012 Dec 26.

PMID:
23743325
50.

Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.

Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K.

Cytotherapy. 2013 Apr;15(4):481-91. doi: 10.1016/j.jcyt.2012.12.004. Epub 2013 Feb 5.

PMID:
23391461

Supplemental Content

Loading ...
Support Center